Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/594420


Zimbabwe Pharmaceuticals and Healthcare Report Q1 2008


Description: The Zimbabwe Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Zimbabwe's pharmaceuticals and healthcare industry.

The struggling Zimbabwean economy, hyperinflation and the isolationist and internationally unacceptable government policy will continue to stifle recovery of the country’s once relatively buoyant pharmaceutical market. Most recently, the lack of foreign currency – necessary for the purchase of active pharmaceutical ingredients (APIs) from abroad – has prompted the local pharmaceutical industry representatives to call on the government for assistance. While some domestic producers have respectable production facilities, the country is 90%-reliant on imported APIs.

In the meantime, the cost of essential drugs has sky-rocketed as the country's economic crisis continues to worsen. The increased trend for pharmacies to import finished drugs using foreign currency sourced from the parallel market has resulted in most of the population – including the people eligible for medical aid schemes – now having no access to essential drugs. BMI expects another year of negative real GDP growth in 2008, with domestic investment remaining non-existent. Those international companies still operating in Zimbabwe have already written-off their investments, but should these be pushed to cede majority control, as the government plans, they will simply leave the country.

With no improvement in sight, by the end of 2012, the country’s pharmaceutical market is forecast to fall to US$4.3mn, from an estimated US$4.5mn in 2007. Rampant counterfeiting, difficult political and economic environments and the biased regulatory regime will continue to render imports minimal, as will the virtual collapse of the official healthcare system. On the other hand, charity and other international efforts, such as donations of essential medicines for the treatment of prevalent infectious disease in the country will continue to distort the real figures. Increasingly, traditional medicines and alternative treatments will become the only options for the bulk of the population on low incomes. The HIV/AIDS epidemic is slowly coming under control, although about 18% of the total population is infected.

Given the above issues, Zimbabwe was once again ranked last in BMI’s adjusted Business Environment Rankings for the Middle East & Africa (MEA) region, with its score but a fraction of the scores received by leading markets. Endemic corruption both in the health service and among government officials has also helped create a burgeoning black market – with at least 80% of total economic activity now thought to be informal – and the government has been criticised for doing little to change the situation, as well as for measures preventing positive changes.

As a result, local companies are looking abroad for revenue, although the need to import raw materials renders even this proposition difficult. CAPS Holding and Five Plus Pharmaceuticals are the latest firms aiming to penetrate other African markets in a bid to avoid dire situation at home.


Contents: Executive Summary
Zimbabwe Pharmaceuticals And Healthcare Industry SWOT
Zimbabwe Political SWOT
Zimbabwe Economic SWOT
Zimbabwe Business Environment SWOT
Pharmaceutical Business Environment Ratings
Pharmaceutical Ratings – Revised Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Zimbabwe – Business Environment Ranking
Table: Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Zimbabwe – Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Public Drug Procurement
Industry Developments
Health Profile
Table: Key Health Indicators
HIV/AIDS Crisis
Recent Regional HIV/AIDS Developments
Healthcare System
Healthcare Funding
Healthcare Staff
Pharmaceutical Sector
Recent Pharmaceutical Sector Developments
Table: ARV Prices Available Through Direct Purchase From Roche (CHF)
Traditional Medicine
Biotechnology Sector Developments
Industry Forecast Scenario
Overall Market Forecasts
Table: Zimbabwe’s Drug Market Forecasts
Key Growth Factors – Industry
Table: Zimbabwe’s Healthcare Expenditure Indicators
Key Growth Factors –Macroeconomic
Table: Zimbabwe’s Economic Outlook
Prescription Market Forecast
Table: Zimbabwe Prescription Drug Market Forecast (US$mn unless otherwise stated)
OTC Market Forecast
Table: Zimbabwe OTC Market Forecast (US$mn unless otherwise stated)
Generics And Patented Market Forecast
Table: Zimbabwe Generics And Patented Market Forecast
Export/Import Forecasts
Table: Zimbabwe Import/Domestic Market Forecast (%)
Other Healthcare Data Forecasts
Table: Zimbabwe Other Healthcare Forecasts
Key Risks To BMI Forecasts
Competitive Landscape
Company Profiles
Multinational Companies
Ranbaxy
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
GlaxoSmithKline
Indigenous Companies
Datlabs
Varichem Laboratories
CAPS Holdings
BMI Forecast Modelling.
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources


Companies Mentioned Ranbaxy Pfizer Novartis Sanofi-Aventis Merck & Co GlaxoSmithKline Indigenous Companies Datlabs Varichem Laboratories CAPS Holdings


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/594420

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 08/09/2008 04:11:00
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Zimbabwe Pharmaceuticals and Healthcare Report Q1 2008
Web Address:
http://www.researchandmarkets.com/reports/594420
Office Code:
OCHHIKIMMSX

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00




Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 08/09/2008 04:11:00

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World